Stochastic Pharmacokinetic-Pharmacodynamic Modeling for Assessing the Systemic Health Risk of Perfluorooctanoate (PFOA)
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
A phase 1 dose-escalation trial assessed the chemotherapeutic potential of ammonium perfluorooctanoate (APFO). Forty-nine primarily solid-tumor cancer patients who failed standard therapy received weekly APFO doses (50-1200 mg) for 6 weeks. Clinical chemistries and plasma PFOA (anionic APFO) were measured predose and weekly thereafter. Several clinical measures including total cholesterol, high-density lipoproteins (HDLs), thyroid stimulating hormone (TSH), and free thyroxine (fT4), relative to PFOA concentrations were examined by: Standard statistical analyses using generalized estimating equations (GEE) and a probabilistic analysis using probability distribution functions (pdf) at various PFOA concentrations; and a 2-compartment pharmacokinetic/pharmacodynamic (PK/PD) model to directly estimate mean changes. Based on the GEE, the average rates of change in total cholesterol and fT4 associated with increasing PFOA were approximately -1.2×10-3 mmol/l/μM and 2.8×10-3 pmol/l/μM, respectively. The PK/PD model predicted more closely the trends observed in the data as well as the pdfs of biomarkers. A decline in total cholesterol was observed, with a clear transition in shape and range of the pdfs, manifested by the maximum value of the Kullback-Leibler (KL) divergence, that occurred at plasma PFOA between 420 and 565 μM (175 000-230 000 ng/ml). High-density lipoprotein was unchanged. An increase in fT4 was observed at a higher PFOA transition point, albeit TSH was unchanged. Our findings are consistent with some animal models and may motivate re-examination of the epidemiologic studies to PFOA at levels several orders of magnitude lower than this study. These observational studies have reported contrary associations, but currently understood biology does not support the existence of such conflicting effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global Sensitivity Analysis. The Primer
Saltelli, A., Ratto, M., Andres, T., Campolongo, F., Cariboni, J., Gatelli, D., Saisana, M., & Tarantola, S. (2007) · doi:10.1002/9780470725184 · Cited by 6,430
Olsen, G. W., Burris, J. M., Ehresman, D. J., Froehlich, J. W., Seacat, A. M., Butenhoff, J. L., & Zobel, L. R. (2007) · Environmental Health Perspectives · doi:10.1289/ehp.10009 · Cited by 2,049
Self-citationDose Escalation Methods in Phase I Cancer Clinical Trials
Le Tourneau, C., Lee, J. J., & Siu, L. L. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp079 · Cited by 867
The toxicology of perfluorooctanoate
Kennedy, G. L., Butenhoff, J. L., Olsen, G. W., O'Connor, J. C., Seacat, A. M., Perkins, R. G., Biegel, L. B., Murphy, S. R., & Farrar, D. G. (2004) · Critical Reviews in Toxicology · doi:10.1080/10408440490464705 · Cited by 742
Self-citationEpidemiologic Evidence on the Health Effects of Perfluorooctanoic Acid (PFOA)
Steenland, K., Fletcher, T., & Savitz, D. A. (2010) · Environmental Health Perspectives · doi:10.1289/ehp.0901827 · Cited by 660
Nelson, J. W., Hatch, E. E., & Webster, T. F. (2010) · Environmental Health Perspectives · doi:10.1289/ehp.0901165 · Cited by 538 · cited 4×
“…studies of general populations have reported positive associations be-tween serum cholesterol (primarily LDL) and PFOA (Eriksen et al. , 2013; Geiger et al. , 2014; Nelson et al. , 2010; Starling et al. , 2014) at approximately 4 orders of magnitude lower concentrations than in this phase 1 study.”
BackgroundInfluentialMelzer, D., Rice, N., Depledge, M. H., Henley, W. E., & Galloway, T. S. (2010) · Environmental Health Perspectives · doi:10.1289/ehp.0901584 · Cited by 496
Pitfalls in the measurement and interpretation of thyroid function tests
Koulouri, O., Moran, C., Halsall, D., Chatterjee, K., & Gurnell, M. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.10.003 · Cited by 282
Shepherd, J., Kastelein, J. J. P., Bittner, V., Deedwania, P., Breazna, A., Dobson, S., Wilson, D. J., Zuckerman, A., & Wenger, N. K. (2007) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04371206 · Cited by 275
Frisbee, S. J., Shankar, A., Knox, S. S., Steenland, K., Savitz, D. A., Fletcher, T., & Ducatman, A. M. (2010) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpediatrics.2010.163 · Cited by 274 · cited 2×
“An association between high cholesterol and measured PFOA (Fitz-Simon et al. , 2013; Frisbee et al. , 2010; Steenland et al. , 2009) and model-derived cumulative PFOA (Winquist and Steenland 2014a) has been reported in a mid-Ohio river valley community whose drinking water contained PFOA from a…”
BackgroundRenal elimination of perfluorocarboxylates (PFCAs)
Han, X., Nabb, D. L., Russell, M. H., Kennedy, G. L., & Rickard, R. W. (2012) · Chemical Research in Toxicology · doi:10.1021/tx200363w · Cited by 250
Thirty years of medical surveillance in perfluooctanoic acid production workers
Costa, G., Sartori, S., & Consonni, D. (2009) · Journal of Occupational & Environmental Medicine · doi:10.1097/jom.0b013e3181965d80 · Cited by 238 · cited 2×
“…Wang et al., 2013; Webster et al., 2016; Wen et al., 2013); (2) the mid-Ohio river valley community (Knox et al., 2011; Lopez-Espinosa et al., 2012; Winquist and Steenland 2014b), and (3) occupational studies (Costa et al., 2009; Olsen and Zobel, 2007; Sakr et al., 2007a,b; Steenland et al., 2015).”
BackgroundResultSteenland, K., Tinker, S., Shankar, A., & Ducatman, A. (2010) · Environmental Health Perspectives · doi:10.1289/ehp.0900940 · Cited by 224 · cited 3×
“…chronic kidney disease in children and adults with PFOA (Kataria et al. , 2015; Shankar et al. , 2011a) or with hyperuricemia (Geiger et al. , 2013; Shankar 2011b; Steenland et al. , 2010b); however, these findings were likely confounded by the GFR (Watkins et al. , 2013; Dhingra et al. , 2017).”
BackgroundResultPerfluoroalkyl Chemicals and Chronic Kidney Disease in US Adults
Shankar, A., Xiao, J., & Ducatman, A. (2011) · American Journal of Epidemiology · doi:10.1093/aje/kwr171 · Cited by 166
Watkins, D. J., Josson, J., Elston, B., Bartell, S. M., Shin, H.-M., Vieira, V. M., Savitz, D. A., Fletcher, T., & Wellenius, G. A. (2013) · Environmental Health Perspectives · doi:10.1289/ehp.1205838 · Cited by 158 · cited 8×
“, 2010b); however, these findings were likely confounded by the GFR (Watkins et al., 2013; Dhingra et al., 2017).”
BackgroundInfluentialBjork, J. A., & Wallace, K. B. (2009) · Toxicological Sciences · doi:10.1093/toxsci/kfp093 · Cited by 137
Elcombe, C. R., Elcombe, B. M., Foster, J. R., Farrar, D. G., Jung, R., Chang, S.-C., Kennedy, G. L., & Butenhoff, J. L. (2010) · Archives of Toxicology · doi:10.1007/s00204-010-0572-2 · Cited by 96 · cited 2×
“…rats and mice treated with APFO, liver effects such as increased serum ALT and AST values (Butenhoff et al., 2012a; Minata et al., 2010; Son et al., 2008); peroxisome proliferation with subsequent hepatocellular hypertrophy (Elcombe et al., 2010; Haughom and Spydevold, 1992; Loveless et al., 2006;)”
BackgroundResultSelf-citationPerfluorocarbon exposure, gender and thyroid function in the C8 Health Project
S. Knox, S., Jackson, T., J. Frisbee, S., Javins, B., & M. Ducatman, A. (2011) · The Journal of Toxicological Sciences · doi:10.2131/jts.36.403 · Cited by 95
Butenhoff, J. L., Bjork, J. A., Chang, S.-C., Ehresman, D. J., Parker, G. A., Das, K., Lau, C., Lieder, P. H., van Otterdijk, F. M., & Wallace, K. B. (2012) · Reproductive Toxicology · doi:10.1016/j.reprotox.2011.08.004 · Cited by 75 · cited 6×
“; and increased incidence of hepatocellular adenoma in rats (Biegel et al. , 2001; Butenhoff et al. , 2012a) were reported, but these changes were attributed to PPAR a activation, a mode of action unlikely to result in human liver tumors (Corton et al. , 2014; Das et al. , 2017).”
BackgroundInfluentialRebholz, S. L., Jones, T., Herrick, R. L., Xie, C., Calafat, A. M., Pinney, S. M., & Woollett, L. A. (2016) · Toxicology Reports · doi:10.1016/j.toxrep.2015.11.004 · Cited by 69 · cited 1×
“CETP mice (Westerterp et al. , 2006), in which a Western diet containing APFO resulted in decreased plasma non-HDL cholesterol and triglycerides (Princen et al. , 2016).”
BackgroundRussell, M. H., Waterland, R. L., & Wong, F. (2015) · Chemosphere · doi:10.1016/j.chemosphere.2014.07.061 · Cited by 53 · cited 1×
“For PFOA, serum elimination half-life values range from hours/days (rats), weeks (mice), or months (monkeys) (Butenhoff et al., 2004; Han et al., 2012; Lou et al., 2009), whereas in humans it ranges between 2.3 and 3.5 years (Bartell et al., 2009; Olsen et al., 2007a; Russell et al., 2015).”
BackgroundInfluentialAlbrecht, P. P., Torsell, N. E., Krishnan, P., Ehresman, D. J., Frame, S. R., Chang, S.-C., Butenhoff, J. L., Kennedy, G. L., Gonzalez, F. J., & Peters, J. M. (2013) · Toxicological Sciences · doi:10.1093/toxsci/kfs318 · Cited by 44
Cited by
Fenton, S. E., Ducatman, A., Boobis, A., DeWitt, J. C., Lau, C., Ng, C., Smith, J. S., & Roberts, S. M. (2020) · Environmental Toxicology and Chemistry · doi:10.1002/etc.4890 · Cited by 2,445
Risk to human health related to the presence of perfluoroalkyl substances in food
Panel), E. P. O. C. I. T. F. C. (. C., Schrenk, D., Bignami, M., Bodin, L., Chipman, J. K., del Mazo, J., Grasl‐Kraupp, B., Hogstrand, C., Hoogenboom, L. (., Leblanc, J., et al. (2020) · EFSA Journal · doi:10.2903/j.efsa.2020.6223 · Cited by 989
Goodrum, P. E., Anderson, J. K., Luz, A. L., & Ansell, G. K. (2021) · Toxicological Sciences · doi:10.1093/toxsci/kfaa123 · Cited by 118
The Dilemma of perfluorooctanoate (PFOA) human half-life
Dourson, M., & Gadagbui, B. (2021) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2021.105025 · Cited by 27
Metadata
- Authors
- Convertino, M., Church, T. R., Olsen, G. W., Liu, Y., Doyle, E., Elcombe, C. R., Barnett, A. L., Samuel, L. M., MacPherson, I. R., & Evans, T. R. J.
- Venue
- Toxicological Sciences
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-02-16
- Volume
- 163
- Issue
- 1
- Pages
- 293-306
- ISSN
- 1096-0929 (ISSN-L)
- 1096-6080
- OpenAlex
- W2793420281
- Cited by
- 54
- References
- 22
- FWCI
- 3.07
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.